Early age of onset is an independent predictor for worse disease-free survival in sporadic rectal cancer patients. A comparative analysis of 980 consecutive patients

• Published in: European journal of surgical oncology 2022-04, Vol.48 (4), p.857-863
• Main Authors: Foppa, Caterina, Tamburello, Sara, Maroli, Annalisa, Carvello, Michele, Poliani, Laura, Laghi, Luigi, Malesci, Alberto, Montorsi, Marco, Perea, José, Spinelli, Antonino
• Format: Article
• Language: English
• Subjects: Age of Onset; Dawson-polyoxometalate; Disease-Free Survival; Humans; Inorganic-organic hybrid; Neoplasm Recurrence, Local - pathology; Neoplasm Staging; Prognosis; Progression-Free Survival; Proton conductivity; Rectal Neoplasms - genetics; Rectal Neoplasms - pathology; Rectal Neoplasms - therapy; Retrospective Studies
• ISSN: 0748-7983; 1532-2157
• DOI: 10.1016/j.ejso.2021.10.021

while interest on early-onset colorectal cancer (age ≤49) is on the rise, studies on early-onset rectal cancer (EORC) are limited. The aim of this study was to compare predictors for disease progression/recurrence between sporadic EORC and late-onset RC patients (LORC). 163 EORC and 830 LORC operated between January 1st, 2010 and April 30th, 2021 at a tertiary center were included. Demographics, tumor characteristics, microsatellite status, gene mutations (KRAS, BRAF, NRAS, PI3Kca) and oncologic outcomes were compared. A Cox proportional hazards regression analysis was performed to ascertain the effect of variables on recurrence/progression and death. Recurrence/Progression free survival (R/PFS) and cancer specific survival (CSS) were analyzed by the Kaplan-Meier estimator. Mean age of EORC was 42.16, (46% aged 45–49). A majority of EORC patients had a family history for CRC (p = 0.01) and underwent total neoadjuvant treatment (p = 0.01). EORC patients showed a higher rate of low-grade tumor differentiation (p